WSB2 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the WD repeat and SOCS box-containing protein 2 (WSB2). WSB2 is part of the E3 ubiquitin ligase complex, a multi-protein system that plays a crucial role in the ubiquitination process, which marks proteins for degradation by the proteasome. By inhibiting WSB2, these compounds disrupt its involvement in the ubiquitination pathway, leading to altered protein stability and turnover within cells. The inhibition of WSB2 can result in the modulation of various cellular processes that depend on protein degradation, such as signal transduction, cell cycle regulation, and protein quality control. This makes WSB2 inhibitors of interest in studies focused on understanding the biological mechanisms of protein homeostasis and degradation.
Structurally, WSB2 inhibitors can vary widely, but they typically contain molecular features that allow for specific binding to the WSB2 protein, effectively blocking its ability to interact with its substrate or other components of the E3 ligase complex. Some inhibitors may bind directly to the WD repeat domains, which are important for protein-protein interactions, while others might target the SOCS box domain, which mediates the recruitment of ubiquitin-conjugating enzymes. The specificity of these inhibitors is crucial for studying the precise roles of WSB2 in different biological pathways without interfering with the functions of other proteins in the ubiquitin-proteasome system. This specificity allows researchers to delineate the unique contributions of WSB2 to cellular functions and its regulatory networks, providing deeper insights into the molecular basis of protein degradation.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Could inhibit proteasomal activity, possibly influencing WSB2 protein levels. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
May affect lysosomal degradation, potentially impacting WSB2 protein turnover. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Might inhibit autophagy, potentially affecting WSB2 degradation. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Could inhibit vacuolar H+-ATPase, influencing lysosomal function and WSB2 degradation. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Might inhibit protein synthesis, affecting WSB2 protein levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
May inhibit transcription, affecting WSB2 mRNA levels. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that might influence WSB2 expression through MAPK pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that could affect WSB2 expression via stress response pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
ERK pathway inhibitor that might influence WSB2 expression regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that could impact WSB2 expression through AKT signaling pathways. | ||||||